研究者詳細 - 座間味　義人

論文 - 座間味　義人

分割表示 340 件中 21 - 40 件目／全件表示 >>

Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments. 査読国際誌

Koji Miyata, Yuki Izawa-Ishizawa, Kaito Tsujinaka, Honoka Nishi, Syuto Itokazu, Tatsumi Miyata, Masateru Kondo, Toshihiko Yoshioka, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Maki Sato, Mizusa Hyodo, Hirofumi Hamano, Kei Kawada, Masayuki Chuma, Yoshito Zamami, Koichi Tsuneyama, Mitsuhiro Goda, Keisuke Ishizawa

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 179 117418 - 117418 2024年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

Fluoroquinolones, which are widely used antibiotics, have been linked to aortic disease, which prompted an FDA warning in 2018. Recent reports have challenged the perception that fluoroquinolones pose a significant risk for vascular diseases. This study aimed to investigate whether fluoroquinolones increase the risk of aortic diseases by focusing on the onset of aortic dissection. Levofloxacin (LVFX), a fluoroquinolone, was studied in vitro using cultured vascular cells and in vivo using a mouse model prone to aortic dissection. Risk of adverse drug events was analyzed using VigiBase, a global safety database, and a retrospective cohort analysis was conducted using the JMDC Claims database. LVFX resulted in endothelial cell injury and increased matrix metalloproteinases in vitro. However, in vivo studies showed no significant effect on elastin degradation or aortic dissection incidence. The effect of LVFX on endothelial injury was altered during the onset of dissection, exacerbating injury before onset but inhibiting it afterward. Safety database analysis showed no significant risk signals for aortic dissection associated with fluoroquinolones, which was supported by findings in the receipt database. Inconsistencies were observed in the in vitro and in vivo actions of fluoroquinolones and differences in their effects on aortic dissection and aneurysms. Despite cytotoxicity, the risk of aortic dissection was not significantly increased in clinical scenarios. Based on our findings, concerns regarding aortic diseases do not justify discontinuation of fluoroquinolone use. Further studies are needed to elucidate the conflicting actions of fluoroquinolones, taking into account background pathophysiology such as infection and inflammation.

DOI： 10.1016/j.biopha.2024.117418

PubMed

researchmap

Ameliorating effect of chotosan and its active component, Uncaria hook, on lipopolysaccharide-induced anxiety-like behavior in mice 査読国際誌

Yasumasa Okawa, Soichiro Ushio, Yasuhisa Izushi, Yoshihisa Kitamura, Yoshito Zamami, Toshiaki Sendo

Frontiers in Pharmacology 15 1471602 - 1471602 2024年9月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Frontiers Media SA

Introduction

In this study, we aimed to examine the effects of chotosan, a traditional Japanese botanical drug, and its active component, Uncaria hook, on anxiety-like behaviors induced by systemic inflammation in mice.

Methods

To induce systemic inflammation, the mice were treated with lipopolysaccharide (LPS), a bacterial endotoxin. Prior to LPS treatment, the mice were administered chotosan or Uncaria hook orally each day for 14 days. Anxiety-like behavior of the mice was evaluated using the light–dark test 24 h after LPS treatment.

Results

Repeated administration of chotosan prevented anxiety-like behavior in both normal and LPS-treated mice. Similarly, administration of Uncaria hook suppressed LPS-induced anxiety-like behavior in mice. Furthermore, treatment with tandospirone, a 5-HT_1A receptor agonist, alleviated anxiety-like behavior in mice, whereas treatment with DOI, a 5-HT_2A receptor agonist, enhanced anxiety-like behavior in mice. LPS treatment significantly increased serotonin (5-HT)_2A receptor mRNA expression in the frontal cortex, whereas 5-HT_1A receptor mRNA expression remained unchanged in the hippocampus. Notably, chotosan significantly suppressed the mRNA expression of 5-HT_2A receptor.

Discussion

These findings indicate that chotosan exerts anxiolytic-like effects in the context of inflammation-induced anxiety, potentially mediated by the inhibition of 5-HT_2A receptor hyperfunction in LPS-treated mice. Consequently, we postulate that chotosan may be effective in managing inflammation-induced anxiety-like behaviors.

DOI： 10.3389/fphar.2024.1471602

PubMed

researchmap

ためになる薬の話薬物相互作用(60-慢性疼痛治療薬の薬物相互作用)

高橋徹多, 東恩納司, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 2 ) 80 - 82 2024年8月

mRNAワクチン

田中雄太, 座間味義人

岡山医学会雑誌 136 ( 2 ) 83 - 84 2024年8月

ためになる薬の話薬物相互作用(60-慢性疼痛治療薬の薬物相互作用)

高橋徹多, 東恩納司, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 2 ) 80 - 82 2024年8月

A network-based trans-omics approach for predicting synergistic drug combinations. 査読国際誌

Midori Iida, Yurika Kuniki, Kenta Yagi, Mitsuhiro Goda, Satoko Namba, Jun-Ichi Takeshita, Ryusuke Sawada, Michio Iwata, Yoshito Zamami, Keisuke Ishizawa, Yoshihiro Yamanishi

Communications medicine 4 ( 1 ) 154 - 154 2024年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Combination therapy can offer greater efficacy on medical treatments. However, the discovery of synergistic drug combinations is challenging. We propose a novel computational method, SyndrumNET, to predict synergistic drug combinations by network propagation with trans-omics analyses. METHODS: The prediction is based on the topological relationship, network-based proximity, and transcriptional correlation between diseases and drugs. SyndrumNET was applied to analyzing six diseases including asthma, diabetes, hypertension, colorectal cancer, acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). RESULTS: Here we show that SyndrumNET outperforms the previous methods in terms of high accuracy. We perform in vitro cell survival assays to validate our prediction for CML. Of the top 17 predicted drug pairs, 14 drug pairs successfully exhibits synergistic anticancer effects. Our mode-of-action analysis also reveals that the drug synergy of the top predicted combination of capsaicin and mitoxantrone is due to the complementary regulation of 12 pathways, including the Rap1 signaling pathway. CONCLUSIONS: The proposed method is expected to be useful for discovering synergistic drug combinations for various complex diseases.

DOI： 10.1038/s43856-024-00571-2

PubMed

researchmap

レセプトデータを用いたダサチニブの有効性・安全性に胃酸分泌抑制薬が及ぼす影響の評価

亀沖真希, 牛尾聡一郎, 佐田光, 建部泰尚, 濱野裕章, 座間味義人

The Journal of Toxicological Sciences 49 ( Suppl. ) S128 - S129 2024年7月

免疫チェックポイント阻害薬誘発心筋炎の発症予測モデルの構築

山元黎奈, 濱野裕章, 中込昂希, 座間味義人, 上原孝

The Journal of Toxicological Sciences 49 ( Suppl. ) S126 - S127 2024年7月

COVID-19ワクチン接種後の小児の心筋炎リスクに関する大規模研究

東さくら, 濱野裕章, 座間味義人

The Journal of Toxicological Sciences 49 ( Suppl. ) S125 - S125 2024年7月

大規模データベースを用いたチロシンキナーゼ阻害剤による心臓毒性リスクの評価

井川祐輔, 江角悟, 武田達明, 濱野裕章, 鍛治園誠, 西原茂樹, 村川公央, 座間味義人

The Journal of Toxicological Sciences 49 ( Suppl. ) S90 - S90 2024年7月

Effect of Lipopolysaccharide on the Duration of Zolpidem-Induced Loss of Righting Reflex in Mice. 査読

Yudai Wada, Soichiro Ushio, Yoshihisa Kitamura, Yoshito Zamami, Toshiaki Sendo

Acta medica Okayama 78 ( 3 ) 227 - 235 2024年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Zolpidem, a non-benzodiazepine hypnotic, is primarily used to treat insomnia. In a previous study, pior treatment with non-benzodiazepine receptor agonists was associated with inflammation. The present study aimed to clarify the association between the effects of zolpidem and inflammation in mice treated with lipopolysaccharide (LPS), a known model of inflammation. We assessed the zolpidem-induced loss of righting reflex (LORR) duration 24 h after LPS treatment in mice. Additionally, the expressions of γ-aminobutyric acid (GABA)A receptor subunit and K+-Cl- cotransporter isoform 2 (KCC2) mRNA in the hippocampus and frontal cortex were examined in LPS-treated mice. Pretreatment with LPS was associated with significantly prolonged duration of zolpidem-induced LORR compared to control mice. This effect was significantly attenuated by administering bicuculline, a GABAA receptor antagonist, or flumazenil, a benzodiazepine receptor antagonist, in LPS-treated mice. Compared to controls, LPS-treated mice showed no significant change in the expression of GABAA receptor subunits in the hippocampus or frontal cortex. Bumetanide, an Na+-K+-2Cl- cotransporter isoform 1 blocker, attenuated the extended duration of zolpidem-induced LORR observed in LPS-treated mice. LPS significantly decreased Kcc2 mRNA expression in the hippocampus and the frontal cortex. These findings suggest that inflammation increases zolpidem-induced LORR, possibly through a reduction in KCC2 expression.

DOI： 10.18926/AMO/67197

PubMed

researchmap

医薬品供給問題が採用医薬品に与える影響に関する調査後発医薬品の使用促進および代替薬の確保の点から

槇田崇志, 佐田光, 田中雄太, 濱野裕章, 西原茂樹, 村川公央, 座間味義人

ジェネリック研究 ( 第18回学術大会要旨集 ) 65 - 65 2024年5月

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～小児がん治療における探求的アプローチ

岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人

日本臨床腫瘍薬学会雑誌 36 72 - 72 2024年5月

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～小児がん治療における探求的アプローチ

岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人

日本臨床腫瘍薬学会雑誌 36 72 - 72 2024年5月

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～医療データ解析を起点とした臨床研究の実践

新村貴博, 八木健太, 相澤風花, 石澤有紀, 濱野裕章, 合田光寛, 座間味義人, 石澤啓介

日本臨床腫瘍薬学会雑誌 36 70 - 70 2024年5月

副作用報告データベースを用いたベバシズマブのバイオシミラーの安全性に関する検討

槇田崇志, 藤井緑, 濱野裕章, 座間味義人

日本医薬品情報学会総会・学術大会講演要旨集 26回 132 - 132 2024年5月

医薬品供給問題が採用医薬品に与える影響に関する調査後発医薬品の使用促進および代替薬の確保の点から

槇田崇志, 佐田光, 田中雄太, 濱野裕章, 西原茂樹, 村川公央, 座間味義人

ジェネリック研究 ( 第18回学術大会要旨集 ) 65 - 65 2024年5月

Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. 査読国際誌

Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi

International journal of clinical pharmacy 46 ( 3 ) 745 - 750 2024年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO. METHOD: In total, 40,376 and 38,022 records were extracted from FAERS and VigiBase, and 193 AEs were analysed. The reporting odds ratios (ROR) with 95% confidence interval were calculated using a disproportionality analysis (NIVO-CABO/NIVO-IPI). RESULTS: The reported numbers of immune-related AEs, including myocarditis, colitis, and hepatitis, were significantly higher with NIVO-IPI (ROR = 0.18 for FAERS and 0.13 for VigiBase). Contrarily, the reported numbers of other AEs, including gastrointestinal disorders (ROR = 2.68 and 2.92) and skin and subcutaneous tissue disorders (ROR = 2.94 and 3.55), considered to be potentiated by the combination of NIVO and CABO, were higher with NIVO-CABO. CONCLUSION: Our findings contribute to the selection and clinical management of NIVO-IPI and NIVO-CABO, which minimizes the risk of AEs for individual patients with mRCC by considering distinctive differences in the AE profiles.

DOI： 10.1007/s11096-024-01713-1

PubMed

researchmap

ためになる薬の話薬物相互作用肺癌希少フラクションの分子標的治療薬

奥田浩人, 黒田智, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 1 ) 29 - 32 2024年4月

Burden of depressive disorders in Vietnam from 1990 to 2019: A secondary analysis of the Global Burden of Disease Study 2019. 査読国際誌

Quynh Thi Vu, Ko Harada, Yoshito Nishimura, Hideharu Hagiya, Elizabeth Tan, Odifentse Mapula E Lehasa, Yoshito Zamami, Toshihiro Koyama

Journal of psychiatric research 172 420 - 426 2024年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Depressive disorders are among the leading causes of disability globally. However, information on the burden of depressive disorders in Vietnam is limited. We aimed to analyse the burden of depressive disorders in Vietnam from 1990 to 2019. Using data from the Global Burden of Disease Study 2019, prevalence and disability-adjusted life-years (DALYs) were used as indicators to analyse the burden of depressive disorders by age and sex. In 2019 in Vietnam, depressive disorders comprised 2629.1 thousand (95% uncertainty interval (UI): 2233.3-3155.9) estimated cases and 380.6 thousand (95% UI: 258.9-533.8) estimated DALYs. The crude prevalence rate of depressive disorders was higher among females than among males. The DALYs of depressive disorder accounted for a higher percentage of the total all-cause DALYs in the 10-64-year age group than in other age groups. Major depressive disorder was the largest contributor to the burden of depressive disorders. From 1990 to 2019, the crude prevalence and DALY rates per 100 000 population due to depressive disorders increased significantly, whereas age-standardised rates of prevalence and DALYs decreased significantly; the respective average annual percent changes were 0.88% (95% confidence interval: 0.87 to 0.89), 0.68% (0.66 to 0.70), -0.20% (-0.21 to -0.19), and -0.27% (-0.28 to -0.25). Although the age-standardised prevalence rate was lower than that seen globally, depressive disorders were considerable mental health issues in Vietnam. This study will help governments and policymakers to establish appropriate strategies to reduce the burden of these disorders by identifying the priority areas and individuals.

DOI： 10.1016/j.jpsychires.2024.02.041

PubMed

researchmap

　前のページ - 次のページ　

<座間味 義人>

論文 - 座間味 義人

<座間味　義人>

論文 - 座間味　義人